Art

J-GLOBAL ID：201802221847025623   Reference number：18A1061732

In Vitro Anti-inflammatory Effects of the Phenylbutyric Acid Metabolite Phenylacetyl Glutamine

フェニル酪酸代謝産物,フェニルアセチルグルタミンのin vitro抗炎症作用

Author (5)： Hazekawa Mai (Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University) ,  Ono Kazuhiko (Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University) ,  Nishinakagawa Takuya (Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University) ,  Kawakubo-Yasukochi Tomoyo (Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University) ,  Nakashima Manabu (Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 41  Issue： 6  Page： 961-966(J-STAGE)  Publication year： 2018 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： metabolite ,...
Semi thesaurus term： *anti-inflammatory action ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1061732&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (12)： sodium 4-phenylbutyrate ,  phenylacetyl glutamine ,  cytokine ,  spleen cell ,  peritoneal cavity cell ,  Toll-like receptor 4 ,  sodium 4-phenylbutyrate ,  phenylacetyl glutamine ,  cytokine ,  spleen cell ,  peritoneal cavity cell ,  Toll-like receptor 4

JST classification (1)： Basic research of anti-inflammatory drugs  (GW15010T)

Substance index (2)： 4-Phenylbutyric acid sodium salt ,  N2-(Phenylacetyl)-L-glutamine

Reference (17)：

• 1) Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med., 335, 855-859 (1996).
• 2) Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood, 85, 43-49 (1995).
• 3) Mercuri E, Bertini E, Messina S, Pelliccioni M, D’Amico A, Colitto F, Mirabella M, Tiziano FD, Vitali T, Angelozzi C, Kinali M, Main M, Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord., 14, 130-135 (2004).
• 4) Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs, 25, 131-138 (2007).
• 5) Kusaczuk M, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyric acid: simple structure-multiple effects. Curr. Pharm. Des., 21, 2147-2166 (2015).

Terms in the title (5)： フェニル ,  酪酸 ,  代謝産物 ,  フェニルアセチルグルタミン ,  抗炎症作用